Industry Insights with Crown Bioscience: Targeting T Cells Within the Cancer Immunity Cycle
Saskia De Man, Marrit Putker, and Pirouz Daftarian from Crown Bioscience discuss the impact of T cell-directed immunotherapy on the cancer-immunity cycle.
#ExpertAnswers: Marrit Putker, Saskia De Man, and Pirouz Daftarian on T Cell-Directed Immunotherapy
Marrit Putker, Saskia De Man, and Pirouz Daftarian from Crown Bioscience discuss T cell-directed immunotherapy on the cancer-immunity cycle, including mechanisms and targets capable of modulating and enhancing T cell activity and the application of methods and models including organoids and high content imaging.
Industry Insights with Crown Bioscience: In Vitro Technologies for Studying the Cancer-Immunity Cycle
In this episode of Industry Insights, Rajendra Kumari, PhD, and Gera Goverse, PhD, from Crown Bioscience answer questions about in vivo, in vitro, and ex vivo technologies and methods that can be used for immuno-oncology research along each step of the cancer-immunity cycle.
Industry Insights with Amy Sheng on Nanobodies
This episode of Share Science features Amy Sheng from Sino Biological, who shares how nanobodies are expected to revolutionize antibody-based drug therapies for a wide range of pathological conditions and especially cancer immunotherapy!
What’s Next in Preclinical Cancer Immunotherapy Research?
This webinar will include a panel discussion of key topics in the field of cancer immunotherapy, including new and emerging methods, recent publications, and future directions.
Targeting T Cells Within the Cancer Immunity Cycle
In this webinar, speakers will discuss the role of T cell biology in cancer immunotherapy.
The Cancer-Immunity Cycle: Research Solutions for Preclinical Immuno-Oncology
Cancer immunotherapy has undoubtedly expanded the cancer treatment landscape and improved patient outlook, which can in part be attributed to the recognition of the importance of the cancer-immunity cycle as a whole. In this blog, we provide an overview of the cancer-immunity cycle and highlight some preclinical models that can facilitate cancer immunotherapy research.
